[Gene therapy for retinitis pigmentosa]

Area of Science:

• Ophthalmology
• Genetics
• Biotechnology

Background:

• Retinitis pigmentosa is the leading inherited retinal dystrophy causing blindness.
• Gene therapy represents a groundbreaking approach for treating previously incurable genetic disorders.
• Luxturna® gained FDA and EMA approval in 2017-2018 for specific inherited retinal diseases.

Purpose of the Study:

• To review current advancements in gene therapy for retinitis pigmentosa.
• To discuss the challenges hindering the widespread clinical adoption of gene therapy for retinitis pigmentosa.

Main Methods:

• Literature review of gene therapy research and clinical trials for retinitis pigmentosa.
• Analysis of regulatory approvals and market authorizations for gene therapy products.
• Discussion of technological, economic, and ethical considerations in gene therapy implementation.

Main Results:

• Luxturna® is an approved gene therapy for retinitis pigmentosa linked to RPE65 gene mutations.
• Gene therapy has demonstrated efficacy in treating certain inherited retinal dystrophies.
• Significant technological, economic, and ethical hurdles remain for broader gene therapy application.

Conclusions:

• Gene therapy, exemplified by Luxturna®, offers a promising treatment avenue for retinitis pigmentosa.
• Overcoming challenges in technology, cost, and ethics is crucial for integrating gene therapy into standard medical practice.
• Continued research and development are essential to expand gene therapy's reach for inherited retinal diseases.